MUDr. Jaroslav Mares - ordinace pro TBC a respiracní nemoci
- Address
- lock Available on a paid plan
Asthma Research
The clinic in Strakonice concentrates on asthma and its severe eosinophilic variants, evaluating novel treatments aimed at better symptom control and fewer flare‑ups.
- Targeted biologic agents for T2‑high asthma
- Strategies to reduce eosinophil‑driven inflammation
- Optimization of inhaled corticosteroid regimens
- Biomarker‑guided patient selection
Across eight trials and two investigators, the site delivers critical insights into real‑world effectiveness for patients across the Czech Republic.
COPD Studies
MUDr. Jaroslav Mares – ordinace pro TBC a respiracní nemoci advances care for chronic obstructive pulmonary disease and chronic bronchitis, testing inhaled combinations that aim to improve lung function and lower exacerbation risk.
- Fixed‑dose triple therapy versus dual therapy
- Enhancements in pre‑dose FEV1 measurements
- Reduction of moderate and severe COPD exacerbations
- Ongoing safety monitoring in long‑term use
The research programme supports regional treatment guidelines and offers patients access to emerging inhaled options.
Severe Eosinophilic Asthma Innovations
Dedicated studies explore therapies for severe eosinophilic asthma, focusing on long‑term safety and sustained reduction of exacerbations through advanced antibodies and oral agents.
- Anti‑TSLP monoclonal antibodies
- Long‑acting injectable biologics
- Modulation of eosinophil counts
- Extended open‑label safety extensions
Participants benefit from continuous follow‑up, providing the site with robust data on durability of response.
Biomarkers & Diagnostic Advances
The research team evaluates non‑invasive markers such as fractional exhaled nitric oxide to identify the T2‑high asthma phenotype and personalize therapeutic choices.
- FeNO monitoring to gauge airway inflammation
- Phenotype‑driven treatment algorithms
- Integration of biomarker data into clinical decision‑making
- Development of predictive tools for exacerbation risk
These efforts enhance diagnostic precision and support tailored treatment pathways for respiratory patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Areteia Therapeutics Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Areteia Therapeutics Inc.3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MUDr. Jaroslav Mares - ordinace pro TBC a respiracní nemoci
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled on inhaled corticosteroid and long-acting beta 2 agonist therapy | Rapt Therapeutics Inc. | Phase II | Not Recruiting | Nov 2023 | Jun 2024 |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexpramipexole Dihydrochloride Monohydrate | 3 | Unknown | 2024-04-10 | 2024-10-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.